Advanced Search >

Risk Minimisation Materials

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

This brochure provides important advice on the management of potential renal and bone effects of Tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue